MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies

White, A.D. ; Sibley, L. ; Sarfas, C. ; Morrison, A. ; Gullick, J. ; Clark, S. ; Gleeson, F. ; McIntyre, A. ; Arlehamn, C.L. ; Sette, A. ; Salguero, F.J. ; Rayner, E. ; Rodriguez, E. ; Puentes, E. ; Laddy, D. ; Williams, A. ; Dennis, M. ; Martin, C. (Universidad de Zaragoza) ; Sharpe, S.

Resumen: A single intradermal vaccination with MTBVAC given to adult rhesus macaques was well tolerated and conferred a significant improvement in outcome following aerosol exposure to M. tuberculosis compared to that provided by a single BCG vaccination. Vaccination with MTBVAC resulted in a significant reduction in M. tuberculosis infection-induced disease pathology measured using in vivo medical imaging, in gross pathology lesion counts and pathology scores recorded at necropsy, the frequency and severity of pulmonary granulomas and the frequency of recovery of viable M. tuberculosis from extrapulmonary tissues following challenge. The immune profiles induced following immunisation with MTBVAC reflect those identified in human clinical trials of MTBVAC. Evaluation of MTBVAC- and TB peptide-pool-specific T-cell cytokine production revealed a predominantly Th1 response from poly- (IFN-¿+TNF-a+IL2+) and multi-(IFN-¿+TNF-a+) functional CD4 T cells, while only low levels of Th22, Th17 and cytokine-producing CD8 T-cell populations were detected together with low-level, but significant, increases in CFP10-specific IFN-¿ secreting cells. In this report, we describe concordance between immune profiles measured in clinical trials and a macaque pre-clinical study demonstrating significantly improved outcome after M. tuberculosis challenge as evidence to support the continued development of MTBVAC as an effective prophylactic vaccine for TB vaccination campaigns.

Idioma: Inglés

DOI: 10.1038/s41541-020-00262-8

Año: 2021

Publicado en: npj Vaccines 6, 1 (2021), 4 [10 pp]
ISSN: 2059-0105

Factor impacto JCR: 9.399 (2021)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 21 / 140 = 0.15 (2021) - Q1 - T1
Categ. JCR: IMMUNOLOGY rank: 32 / 163 = 0.196 (2021) - Q1 - T1

Factor impacto CITESCORE: 9.4 - Medicine (Q1) - Immunology and Microbiology (Q1) - Pharmacology, Toxicology and Pharmaceutics (Q1)

Factor impacto SCIMAGO: 2.953 - Immunology (Q1) - Pharmacology (medical) (Q1) - Infectious Diseases (Q1)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)